PRISM BioLab Co.,LTD
Research PRISM BioLab Co.,LTD (206A.T) on Bullrun: market cap JPY 5.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker206A.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 5.14B
- Financial periodFY2025
- RevenueJPY 677.33M
- Revenue growth121.6%
- Net income-JPY 833.70M
- Free cash flow-JPY 1.54B
- Gross margin39.8%
Valuation Snapshot
latest market cap is JPY 5.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 677.33M | -JPY 833.70M | -JPY 1.54B | 39.8% | -22.82 | JPY 2.92B | n/a | JPY 2.71B |
| FY2024 | JPY 305.62M | -JPY 1.05B | -JPY 61.55M | 52.5% | -33.53 | JPY 4.39B | n/a | JPY 3.50B |
| FY2023 | JPY 112.93M | -JPY 526.91M | -JPY 548.40M | 71.1% | -19.09 | JPY 1.13B | n/a | JPY 1.15B |
| FY2022 | JPY 554.40M | JPY 72.96M | JPY 97.25M | 96.5% | 2.06 | JPY 1.69B | n/a | JPY 1.67B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 5.14B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About PRISM BioLab Co.,LTD
PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PRISM BioLab Co.,LTD's market cap?
PRISM BioLab Co.,LTD's market capitalization is JPY 5.14B.
What does PRISM BioLab Co.,LTD do?
PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujisawa, treating Japan.